- Home
- GAME vs NRXP Comparison
GAME vs NRXP Comparison
Compare GAME & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- NRXP
- Stock Information
- Founded
- GAME 2011
- NRXP 2015
- Country
- GAME United States
- NRXP United States
- Employees
- GAME N/A
- NRXP N/A
- Industry
- GAME
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- NRXP Health Care
- Exchange
- GAME Nasdaq
- NRXP Nasdaq
- Market Cap
- GAME 27.2M
- NRXP 32.6M
- IPO Year
- GAME 2009
- NRXP N/A
- Fundamental
- Price
- GAME $1.90
- NRXP $3.24
- Analyst Decision
- GAME Strong Buy
- NRXP Strong Buy
- Analyst Count
- GAME 3
- NRXP 4
- Target Price
- GAME $3.67
- NRXP $28.50
- AVG Volume (30 Days)
- GAME 7.8M
- NRXP 212.8K
- Earning Date
- GAME 08-13-2025
- NRXP 08-13-2025
- Dividend Yield
- GAME N/A
- NRXP N/A
- EPS Growth
- GAME N/A
- NRXP N/A
- EPS
- GAME N/A
- NRXP N/A
- Revenue
- GAME $99,579,536.00
- NRXP N/A
- Revenue This Year
- GAME $6.08
- NRXP N/A
- Revenue Next Year
- GAME $21.94
- NRXP N/A
- P/E Ratio
- GAME N/A
- NRXP N/A
- Revenue Growth
- GAME 77.06
- NRXP N/A
- 52 Week Low
- GAME $0.50
- NRXP $1.10
- 52 Week High
- GAME $2.87
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- GAME 75.08
- NRXP 53.62
- Support Level
- GAME $0.73
- NRXP $2.90
- Resistance Level
- GAME $2.87
- NRXP $3.53
- Average True Range (ATR)
- GAME 0.22
- NRXP 0.20
- MACD
- GAME 0.13
- NRXP -0.04
- Stochastic Oscillator
- GAME 53.88
- NRXP 58.73
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.